Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
30.22
-0.10 (-0.33%)
At close: Feb 11, 2026, 4:00 PM EST
29.77
-0.45 (-1.49%)
After-hours: Feb 11, 2026, 5:28 PM EST
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $164.86M in the quarter ending September 30, 2025, with 162.11% growth. This brings the company's revenue in the last twelve months to $435.83M, up 114.22% year-over-year. In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth.
Revenue (ttm)
$435.83M
Revenue Growth
+114.22%
P/S Ratio
6.08
Revenue / Employee
$1,132,016
Employees
385
Market Cap
2.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.02B |
| Tarsus Pharmaceuticals | 366.10M |
| Adaptive Biotechnologies | 276.98M |
| Arcus Biosciences | 240.00M |
| IDEAYA Biosciences | 214.83M |
| Wave Life Sciences | 109.23M |
| Viridian Therapeutics | 70.79M |
| Beam Therapeutics | 55.70M |
TVTX News
- 7 days ago - Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
- 13 days ago - Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
- 15 days ago - TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewsWire
- 21 days ago - Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
- 4 weeks ago - Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - Business Wire
- 4 weeks ago - Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Travere Therapeutics Provides Corporate Update and 2026 Outlook - Business Wire
- 5 weeks ago - Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire